CA Patent

CA2441077A1 — Substituted carbazoles as inhibitors of spla2

Assigned to Eli Lilly and Co · Expires 2002-10-10 · 24y expired

What this patent protects

Carbazoles of formula (I) with R2 = hydroxyfunctional amide (hydroxamic or esters) are disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

USPTO Abstract

Carbazoles of formula (I) with R2 = hydroxyfunctional amide (hydroxamic or esters) are disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

Drugs covered by this patent

Patent Metadata

Patent number
CA2441077A1
Jurisdiction
CA
Classification
—
Expires
2002-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.